亚洲视频一区二区_AV电影在线免费观看_国模精品视频一区二区_91免费福利视频一区二区_亚洲AV成人精品一区青青草原_国产免费无码视频_亚洲无码在线不卡_亚洲精品永久久久久久_久久超碰精品国产_国产特一级一级一级黄色视频免费的_波多野结衣网址_五月天丁香婷婷蜜桃色_国产精品亚洲一区二区在线观看_免费观看黃色A一级在线视频_国产精品亚洲午夜福利AV

　　2005年本科畢業(yè)于復(fù)旦大學(xué)，2011年博士畢業(yè)于中科院上海生命科學(xué)院生化細(xì)胞所。2012年以博士后身份先后在西南醫(yī)學(xué)中心(UT Southwestern Medical Center)和克利夫蘭診所(Cleveland Clinic Foundation)Nima Sharifi實(shí)驗(yàn)室從事前列腺癌相關(guān)研究。2012年獲美國(guó)國(guó)防部DOD PCRP Fellowship; 2015年獲得Prostate Cancer Foundation Young Investigator Award。2016年11月加入中科院上海生科院生化與細(xì)胞所，任研究員、研究組長(zhǎng)。

　　我國(guó)前列腺癌死亡率和發(fā)病率增長(zhǎng)迅猛，治愈率顯著低于西方國(guó)家，因此針對(duì)我國(guó)人群的前列腺癌精準(zhǔn)診治相關(guān)研究意義重大。本實(shí)驗(yàn)室致力于開展基于人群隊(duì)列、回答臨床問題的轉(zhuǎn)化研究，解析前列腺癌種族異質(zhì)性的表征和機(jī)制，開發(fā)適用于我國(guó)前列腺癌患者的診治新策略，推動(dòng)更精細(xì)的病人分層和個(gè)性化治療策略。實(shí)驗(yàn)室前期發(fā)現(xiàn)了東西方人群藥物代謝的異質(zhì)性，發(fā)現(xiàn)了適用于我國(guó)人群的前列腺癌治療新靶點(diǎn)和相應(yīng)先導(dǎo)化合物（Nature，2015&2016；Cell Rep Med，2022a；Nat Commun，2021；Oncogene，2022；PNAS，2025）；揭示了疾病進(jìn)展過程中代謝重塑特征，并發(fā)現(xiàn)可用于患者代謝分型的內(nèi)源代謝產(chǎn)物（Cell Rep Med，2022b；Prostate，2022；Clin Can Res，2019）；建立組織代謝示蹤系統(tǒng)，發(fā)現(xiàn)惡性前列腺癌相關(guān)代謝特征、篩查方式和防治措施（J Clin Invest，2023；JSBMS，2021）。基于實(shí)驗(yàn)室工作發(fā)起的多項(xiàng)臨床研究和藥物開發(fā)正在推進(jìn)中。

1. Weiwei Yan*, Xun Liu, Xuefeng Qiu, Xuebin Zhang, Jiahui Chen, Kai Xiao, Ping Wu, Chao Peng, Xiaolin Hu, Zengming Wang, Jun Qin, Liming Sun, Luonan Chen, Denglong Wu, Shengsong Huang*, Lichen Yin*, Zhenfei Li*PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression. J Clin Invest.?2024 Aug 15; 134(18): e175023.?doi: 10.1172/JCI175023.
2. Dongyin He^# , Luyao Zhang^# , Leiye Yu^# , Yuhang Zhang^# , Jingjing Chen^# , Leibo Wang , Haoran Hu , Hongyu Liu , Hong Zheng , Jixin Xia , Jiahui Chen , Chenhui Li , Xin Li , Huiru Tang , Jia Liu* , Ruobing Ren* , Youhong Hu* , Zhenfei Li*.?Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy. Proc Natl Acad Sci U S A. 2025 Jul;122(26):e2422267122. doi: 10.1073/pnas.2422267122. Epub 2025 Jun 25.
3. Weiwei Yan*, Xun Liu, Xuefeng Qiu, Xuebin Zhang, Jiahui Chen, Kai Xiao, Ping Wu, Chao Peng, Xiaolin Hu, Zengming Wang, Jun Qin, Liming Sun, Luonan Chen, Denglong Wu, Shengsong Huang*, Lichen Yin*, Zhenfei Li*PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression. J Clin Invest.?2024 Aug 15; 134(18): e175023.?doi: 10.1172/JCI175023.
4. Xuebin Zhang#, Zengming Wang#, Shengsong Huang#, Dongyin He#, Weiwei Yan, Qian Zhuang, Zixian Wang, Chenyang Wang, Qilong Tan, Ziqun Liu, Tao Yang, Ying Liu, Ruobing Ren, Jing Li, William Butler, Huiru Tang, Gong-Hong Wei, Xin Li*, Denglong Wu*, Zhenfei Li*, Active DHEA uptake in the prostate gland correlates with aggressive prostate cancer. J Clin Invest.?2023 Dec 15;133(24):e171199.?doi: 10.1172/JCI171199.
5. Qilong Tan ^#, Ziqun Liu ^#, Xiaobo Gao ^#, Yibo Wang ^#, Xuefeng Qiu, Jiahui Chen, Liuchun Liang, Hongqian Guo, Shengsong Huang, Denglong Wu,Bing Zhou*, Ronggui Hu*, Zhenfei Li* Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors. Oncogene. Sep 16.?doi: 10.1038/s41388-022-02467-8.
6. Zejie Mei^#, Tao Yang^#, Ying Liu, Yuanyuan Gao, Zemin Hou, Qian Zhuang, Dongyin He, Xuebin Zhang, Qilong Tan, Xuyou Zhu, Yingyi Qin, Xi Chen, Chengdang Xu, Cuidong Bian, Xinan Wang, Chenyang Wang, Denglong Wu, Shengsong Huang*, Zhenfei Li*. Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment. Cell Reports Medicine. 2022 May 17; 3(5):100608. DOI: 10.1016/j.xcrm.2022.10060.
7. Zemin Hou^#, Shengsong Huang^#, Zejie Mei^#, Longlong Chen^#, Jiacheng Guo, Yuanyuan Gao, Qian Zhuang, Xuebin Zhang, Qilong Tan, Tao Yang, Ying Liu, Yongnan Chi, Lifengrong Qi, Ting Jiang, Xuefeng Shao, Yan Wu, Xiaojun Xu, Jun Qin, Ruobing Ren, Huiru Tang* Denglong Wu*, Zhenfei Li*. Inhibiting 3bHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer. Cell Reports Medicine. 2022 March; 3 (3), 100561.
8. Zemin Hou^#, Tao Yang^#, Zejie Mei, Si Zhang, Yuanyuan Gao, Xi Chen, Qilong Tan, Xuyou Zhu, Chengdang Xu, jianpo Lian, Cuidong Bian, Ying Liu, Wei Le, Nazarov Hydyr, Denglong Wu, Luonan Chen, Shengsong Huang*, Zhenfei Li*. Tracing steroidogenesis in prostate biopsy samples to unveil prostate tissue androgen metabolism characteristics and potential clinical application. J Steroid Biochem Mol Biol. ?2021 Jun; 210:105859. doi: 10.1016/j.jsbmb.2021.105859.
9. Yufei Han#, Qian Zhuang#, Bo Sun#, Wenping Lv#, Sheng Wang#, Qingjie Xiao, Bin Pang, Youli Zhou, Fuxing Wang, Pengliang Chi, Qisheng Wang, Zhen Li, Lizhe Zhu, Fuping Li, Dong Deng*, Ying-Chih Chiang*,?Zhenfei Li*,?Ruobing Ren*. Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism. Nat Commun. 2021 Jan 19; 12(1):449.?
10. Xiaomei Gao^#, Charles Dai^#, Shengsong Huang^#, Jingjie Tang^#, Guoyuan Chen, Jianneng Li, Ziqi Zhu, Xuyou Zhu, Shuirong Zhou, Yuanyuan Gao, Zemin Hou, Zijun Fang, Chengdang Xu, Jianyang Wang, Denglong Wu*, Nima Sharifi*, Zhenfei Li*. Functional silencing of HSD17B2 in prostate cancer promotes disease progression. Clin Cancer Res. 2019, 25(4): 1291~1301.
11. Mohammad Alyamani^#, Zhenfei Li^#, Michael Berk, Jianneng Li,Jingjie Tang, Sunil K Upadhyay, Richard J Auchus, Nima Sharifi. Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities. Cell Chem Biol. 2017 Jul 20;24(7):825-832. (^#co-first author)
12. Zhenfei Li, Mohammad Alyamani, Jianneng Li, Kevin Rogacki, M Abazeed, Sunil K Upadhyay, Steven P Balk, Maryellen Taplin, Richard J Auchus, Nima Sharifi. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature, 2016, 533(7604): 547-551.
13. Zhenfei Li, Andrew C Bishop, Mohammad Alyamani, Jorge A Garcia, Robert Dreicer, Dustin R Bunch, Jiayan Liu, Sunil K Upadhyay, Richard J Auchus, Nima Sharifi. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature, 2015, 523(7560).
14. Zhenfei Li^#, Fen Nie^#, Sheng Wang, Lin Li. Histone H4 Lys 20 monomethylation by histone methylase SET8 mediates Wnt target gene activation. Proc Natl Acad Sci USA, 2011, 108(8): 3116-3123. (*co-first author)